Welcome to our dedicated page for IQVIA Holdings news (Ticker: IQV), a resource for investors and traders seeking the latest updates and insights on IQVIA Holdings stock.
IQVIA Holdings Inc. (symbol: IQV) is a prominent player in the healthcare industry, formed from the merger of Quintiles and IMS Health in 2016. The company operates as a global leader in integrated information and technology solutions, driving advancements in healthcare. With a workforce of approximately 50,000 employees across more than 100 countries, IQVIA is dedicated to helping clients improve their clinical, scientific, and commercial outcomes.
Core Services:
- Research and Development (R&D): IQVIA provides outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. This segment focuses on delivering comprehensive research services to advance medical innovations.
- Technology and Analytics: The company offers aggregated information and technology services, catering to pharmaceutical companies, healthcare providers, payers, and policymakers. IQVIA's data and analytics capabilities extend to clinical trials, including virtual trials, ensuring efficient and effective trial outcomes.
- Contract Sales: IQVIA also maintains a small contract sales business, supporting the commercial needs of its clients.
Recent Achievements and Projects:
IQVIA continues to make significant strides in protecting individual patient privacy while leveraging healthcare data to deliver critical real-world disease and treatment insights. The company's commitment to innovation is evident in its ongoing projects and partnerships aimed at enhancing healthcare outcomes globally.
For more information, visit www.quintilesims.com.
IQVIA (NYSE:IQV) has secured a contract from the European Medicines Agency (EMA) to provide analytics services for the DARWIN EU® Coordination Centre, managed by Erasmus University Medical Center Rotterdam. This initiative aims to establish a pan-European network of real-world healthcare data systems, enhancing the regulatory decision-making process for drug safety and effectiveness. Over two years, IQVIA will contribute technical expertise and management for pharmacovigilance data, improving data standardization and accessibility for regulatory agencies.
IQVIA (NYSE:IQV) has launched OCE+, an upgrade to its customer engagement platform. This innovation introduces the Next Best recommendation engine, providing AI-driven suggestions to healthcare professionals (HCP) for optimized engagement. OCE+ aims to enhance productivity, the HCP experience, and return on investment (ROI). By integrating sophisticated data analytics and AI, it facilitates informed decision-making for life sciences teams, promoting better personalization and increased efficiency in customer interactions.
IQVIA Holdings Inc. (NYSE:IQV) announced the appointment of Costa Panagos as president of its Research & Development Solutions unit, succeeding Richard Staub III, who is retiring after over three decades. Panagos, with 25 years of industry experience, was previously the president of R&D Operations and CEO of Q2 Solutions. His effective date is April 1, 2022. Richard Staub will remain with the company as a senior advisor, aiding in business development and client management. This transition is expected to be quick and seamless, as per CEO Ari Bousbib.
IQVIA Holdings Inc. (NYSE:IQV) announced that Ron Bruehlman, CFO, will speak at the Barclays Global Healthcare Conference in Miami, FL on March 16, 2022, at 1:35 p.m. ET. A live audio webcast of the presentation will be accessible via the IQVIA Investor Relations website, with a replay available later that day. IQVIA is a global leader in advanced analytics and clinical research services for the life sciences sector, operating in over 100 countries with approximately 79,000 employees and focusing on improving healthcare outcomes through innovative solutions.
IQVIA has entered into a multi-year collaboration with argenx SE to develop new indications for VYVGART™ (efgartigimod alfa fcab), an FDA-approved treatment for generalized myasthenia gravis. The undisclosed terms of the agreement will enhance clinical development, regulatory, and commercial strategies. IQVIA aims to support argenx in accelerating this process, leveraging its expertise in analytics and technology. With approximately 79,000 employees operating in over 100 countries, IQVIA continues to emphasize its role in improving healthcare outcomes.
IQVIA Holdings reported a strong fourth quarter with revenue of $3,636 million, up 10.2% year-over-year. GAAP net income surged by 167.2% to $318 million, translating to earnings per share of $1.63. Adjusted EBITDA reached $828 million, representing a 12.7% increase. For 2022, IQVIA reaffirmed its revenue guidance of $14.7 billion to $15 billion and raised expectations for Adjusted EBITDA and Earnings per Share. The contracted backlog in R&D Solutions grew to $24.8 billion, indicating strong future revenue potential.
IQVIA Holdings Inc. (NYSE:IQV) announced that Ron Bruehlman, CFO, will participate in a virtual fireside chat at Citi’s 2022 Virtual Healthcare Conference on Thursday, February 24, 2022, at 11:00 a.m. ET. A live audio webcast will be available on the IQVIA Investor Relations website, with a replay accessible later that day. IQVIA is a global leader in analytics and clinical research services for life sciences, operating in over 100 countries with approximately 79,000 employees, focusing on improving healthcare outcomes through insights and technology.
FAQ
What is the current stock price of IQVIA Holdings (IQV)?
What is the market cap of IQVIA Holdings (IQV)?
What is IQVIA Holdings Inc.?
What services does IQVIA offer?
How many employees does IQVIA have?
What is IQVIA's focus in the research and development segment?
What is the role of IQVIA's technology and analytics segment?
Does IQVIA conduct virtual clinical trials?
What industries does IQVIA serve?
How does IQVIA protect patient privacy?
Where can I find more information about IQVIA?
When was IQVIA formed?
